secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-06-23T11:51:12+00:00
Accession:  0001140361-26-026031
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reaches FDA agreement on Phase 3 endpoint for belapectin in MASH cirrhosis
--------------------------------------------------------------------------------

- FDA agreed on primary endpoint: composite liver outcome including prevention of large esophageal varices (>5 mm).
- Company to submit Phase 3 protocol in Q3 2026; plans to evaluate single 2 mg dose of belapectin.
- Galectin actively exploring strategic and financial partnerships to support development and commercialization.
- FDA acknowledged substantial unmet medical need in MASH cirrhosis patients with portal hypertension.
- Company expects Phase 3 trial size comparable to NAVIGATE trial (global Phase 2b/3).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126026031/0001140361-26-026031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126026031/ef20076593_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-026031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer